Prognostic value of morphologic and clinical parameters in pT2-pT3 prostate cancer

International Braz J Urol

Volumn 33, Issue 5, 2007, Pages 662-672

  de Almeida, Jose C ^a,b   Menezes, Raissa P ^a   Kuckelhaus, Selma A ^a   Bocca, Anamelia L ^a   Figueiredo, Florencio ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Biopsy; Immunohistochemistry; Pathology; Prognosis; Prostatectomy; Prostatic neoplasms

Indexed keywords

EID: 36649029791     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/s1677-55382007000500007     Document Type: Article

References (33)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 23-47. Erratum in: CA Cancer J Clin 2002; 52:119. CA Cancer J Clin 2002; 52:181-2.
2. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000; 85: 60-7.
3. Chatelard PP; Groupe De Travail Du: Standards, options and recommendations for the management of prostate cancer: therapeutic decision criteria. Bull Cancer. 2002; 89:619-34. Erratum in: Bull Cancer. 2002; 89:975.
4. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002; 167:528-34.
5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-46. Erratum in: N Engl J Med. 2004; 351: 1470.
6. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277: 1445-51. Erratum in: JAMA 1997; 278: 118.
7. Hernandez J, Thompson IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004; 101: 894-904.
8. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V: Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998; 52: 1079-84.
9. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M: Novel artificial neural network for early detection of prostate cancer. J Clin Oncol. 2002; 20: 921-9.
10. Rubin MA: Using molecular markers to predict outcome. J Urol. 2004; 172: S18-21; discussion S21-2.
11. International Union Against Cancer (UICC): TNM Classification of malignant tumours. In: Sobin LH, Wittekind Ch (Eds.), sixth edition, New York, Wiley-Liss. 2002; pp. 184-7.
12. Srigley JR, Amin MB, Epstein JI, Grignon DJ, Humphrey PA, Renshaw AA, et al.: Protocol applies to invasive carcinomas of the prostate gland. In: http://www.cap.org/apps/cap.portal?_nfpb=true&¶geLabel=home. 2005.
13. AJCC cancer staging manual. In: Greene FL, Page DL, Fleming ID (eds.), sixth edition, New York, Springer. 2002; pp.337-46.
14. Diblasio CJ, Kattan MW: Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology. 2003; 62 Suppl 1: 9-18.
15. Djavan B & Lange P: Epidedmiology, screening and biomarkers for prostate cancer. Prostate Cancer annual updating. 2005. Vol. 3-41.
16. Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, et al.: NCCN Practice Guidelines for Prostate Cancer. Oncology. 2000; 14: 111-9.
17. Krumholtz; JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, et al.: Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology. 2002; 60:469-73.
18. Chan TY, Chan DY, Stutzman KL, Epstein JI: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol. 2001; 166: 2181-4.
19. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111:58-64.
20. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al.: Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 2003; 61: 589-95.
21. Downing SR, Russell PJ, Jackson P: Alterations of p53 are common in early stage prostate cancer. Can J Urol. 2003; 10: 1924-33.
22. Borre M, Stausbol-Gron B, Overgaard J: p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol. 2000; 164: 716-21.
23. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr: p53, bcl-2 and retinoblastoma proteins as longterm prognostic markers in localized carcinoma of the prostate. J Urol. 1997; 158: 131-7.
24. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson P: Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology. 2000; 56: 1011-5.
25. Cerovic SJ, Brajuskovic GR, Vukotic Maletic VD, Micic SR: Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl. 2004; 61: 513-8.
26. Karseladze AI, Rytin IIe, Budunova IV: Immunohistochemical study of the prostate-specific antigen in prostatic cancer. Arkh Patol. 2004; 66: 3-7.
27. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI: E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology. 1999; 53: 707-13.
28. Isaacs JT, Isaacs WB: Androgen receptor outwits prostate cancer drugs. Nat Med. 2004; 10: 26-7.
29. Wu HC, Lai MT, Wu CI, Chen HY, Wan L, Tsai FJ, et al.: E-cadherin gene 3′-UTR C/T polymorphism is associated with prostate cancer. Urol Int. 2005; 75: 350-3.
30. Wieder JA, Soloway MS: Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 1998; 160: 299-315.
31. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, et al.: Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2005; 174: 903-7.
32. Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K, et al.: A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol. 2003; 170: 1203-8.
33. Quintal MM, Magna LA, Guimaraes MS, Ruano T, Ferreira U, Billis A: Prostate cancer pathologic stage pT2b (2002 TNM staging system): does it exist? Int Braz J Urol. 2006; 32:43-7.